The aim of the present study was to develop solid lipid nanoparticles (SLN) of
albendazole (ABZ) and evaluate its efficacy in mice model after oral administration.
Various solid lipids were screened on the basis of solubility of the drug. SLN of
ABZ were prepared by phase inversion temperature method using Compritol 888 ATO
as a lipid with Cremophor EL and Tween 80 as surfactants. Effect of lipid concentration
and drug con- centration on mean particle size and entrapment efficiency was
evaluated. Optimized formulation was characterized by Transmission electron microscopy
(TEM), Differential scanning calorimetry (DSC), and X-ray diffraction (XRD).
In vitro drug release was evaluated using dialysis bag diffusion technique. The anthelmintic
efficacy of ABZ-SLN was evaluated in mice infected with Toxocara canis
larvae. The mean particle size of ABZ-SLN was found to be in the range of 116±3.51
nm - 168.3±3.92 nm and entrapment efficiency wer e found to be in the range of
82.99±2.22% -89.72±1.95% depending on the drug concentration. TEM analysis revealed
that nanoparticles were almost geometrical in shape. DSC thermograms and
XRD pattern revealed amorphinization of ABZ in SLN matrix. In vitro drug release
profile of ABZ-SLN in simulated gastrointestinal conditions demonstrated a prolonged
release pattern wherein maximum release was found to be 92.66±1.7% in 24hr. The
anthelmintic efficacy study confirmed the reduction in larvae count in the liver, lung,
brain and kidney. Based on the results it can be concluded that solid lipid nanoparticles
of ABZ could be a promising formulation for the treatment of Toxocara canis infection.
Keywords: Toxocara canis, visceral larva migrans, Albendazole, Solid lipid nanoparticle, in vivo
Rights & PermissionsPrintExport